Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
September 29 2023 - 5:24PM
Business Wire
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology
company discovering and developing allogeneic gamma delta T cell
therapies for cancer, today announced it granted inducement awards
on September 29, 2023.
Four individuals were hired by Adicet in September 2023. In the
aggregate, Adicet granted new hires non-qualified stock options to
purchase 32,200 shares of Adicet’s common stock with an exercise
price of $1.37 per share, the closing price of Adicet’s common
stock as reported by Nasdaq on September 29, 2023. One-fourth of
the shares underlying each employee’s option will vest on the
one-year anniversary of each recipient’s start date and thereafter
the remaining three-fourths of the shares underlying each
employee’s option will vest in thirty-six substantially equal
monthly installments, such that the shares underlying the option
granted to each employee will be fully vested on the fourth
anniversary of the recipient’s start date, in each case, subject to
each such employee’s continued employment with Adicet on such
vesting dates.
All of the above-described awards were granted outside of
Adicet’s stockholder-approved equity incentive plans pursuant to
Adicet’s 2022 Inducement Plan (the Inducement Plan), which was
adopted by the board of directors in January 2022 and subsequently
amended in January 2023. The awards were authorized by the
compensation committee of the board of directors, which is
comprised solely of independent directors, as a material inducement
to the employees entering into employment with Adicet in accordance
with Nasdaq Listing Rule 5635(c)(4).
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company
discovering and developing allogeneic gamma delta T cell therapies
for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma
delta T cells, engineered with chimeric antigen receptors (CARs)
and chimeric antigen adaptors (CAds), to enhance selective tumor
targeting and facilitate innate and adaptive anti-tumor immune
response for durable activity in patients. For more information,
please visit our website at https://www.adicetbio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230929255155/en/
Adicet Bio, Inc. Investor and Media Contacts Anne
Bowdidge abowdidge@adicetbio.com Janhavi Mohite Stern Investor
Relations, Inc. 212-362-1200 janhavi.mohite@sternir.com
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From Aug 2024 to Sep 2024
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From Sep 2023 to Sep 2024